Pseudomonas aeruginosa surface antigen

Pseudomonas aeruginosa surface antigens are a diverse group of molecules located on the outer surface of the Gram-negative bacterium P. aeruginosa, including lipopolysaccharides (LPS), outer membrane proteins (OMPs), and exopolysaccharides like alginate and Psl [2, 6]. These antigens play critical roles in the bacterium's pathogenicity by facilitating adhesion to host tissues, promoting biofilm formation, and enabling evasion of the host immune system [7, 15]. Because P. aeruginosa is a leading cause of multidrug-resistant infections, particularly in patients with cystic fibrosis or those on ventilators, these surface antigens have become primary targets for non-traditional therapeutic strategies such as monoclonal antibodies and vaccines [3, 4]. Drugs targeting these antigens, such as Panobacumab or MEDI3902, work by enhancing opsonophagocytic killing or neutralizing specific virulence factors like the Type III secretion system protein PcrV [3, 10]. Additionally, some antibiotics like colistin interact directly with surface LPS to disrupt the bacterial membrane [8, 10]. Despite their potential, a major challenge in targeting these antigens is the high degree of phenotypic and genotypic variability among P. aeruginosa strains, which often necessitates the use of multi-target or serotype-specific approaches [3, 14]. This variability can lead to therapeutic failure if the specific antigen targeted is not expressed by the infecting strain [3].

Other names

P. aeruginosa surface antigensPseudomonas antigensBacterial surface antigens (P. aeruginosa)Pseudomonas aeruginosa somatic antigen

Drugs targeting these antigens typically work through opsonophagocytic killing (OPK), neutralization of virulence factors (e.g., PcrV), inhibition of bacterial adhesion to host cells, or direct disruption of the bacterial outer membrane (e.g., polymyxins).